戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 of continuous enrollment after completion of isotretinoin.
2 erience acne relapse and require retrials of isotretinoin.
3 ent included hu14.18K322A, GM-CSF, IL-2, and isotretinoin.
4 boratory monitoring in patients treated with isotretinoin.
5 evaluated prior to and during treatment with isotretinoin.
6 nancy, and in patients taking amiodarone and isotretinoin.
7 feel protected from the teratogenic risks of isotretinoin.
8 6%) and 191 controls (0.44%) were exposed to isotretinoin.
9 fore myeloablative therapy, followed by oral isotretinoin.
10 dent cases of IBD associated with the use of isotretinoin.
11 isk for IBD, including UC or CD, with use of isotretinoin.
12 higher than that used in previous studies of isotretinoin.
13 olved in the durable therapeutic response to isotretinoin.
14  with class D or X prescriptions, except for isotretinoin.
15 ytes that were treated with PPAR ligands and isotretinoin.
16                                              Isotretinoin (13-cis retinoic acid (13-cis RA)) is the m
17                                              Isotretinoin (13-cis retinoic acid) is frequently prescr
18  for NB includes treatment with the retinoid isotretinoin (13-cis retinoic acid; 13cRA), which is use
19  performed using the following search terms: isotretinoin, 13-cis-retinoic acid, Accutane, retinoids,
20 viously received antibiotics (31 [66.0%]) or isotretinoin (32 [68.1%]).
21 r RPE-related eye diseases and the acne drug isotretinoin (a retinoid cycle inhibitor) are discussed.
22                                              Isotretinoin, a known teratogen, is strictly regulated t
23 hich when severe, may require treatment with isotretinoin, a known teratogen.
24                                              Isotretinoin (Accutane) has been shown to slow the synth
25 acne treatment, such as oral antibiotics and isotretinoin (Accutane), have limited use.
26                                              Isotretinoin also blocked the slower, age-dependent accu
27 y treating the abcr(-/-) mice with Accutane (isotretinoin), an inhibitor of rhodopsin regeneration.
28                                              Isotretinoin, an effective anti-acne therapy, is a known
29      HPLC analysis of ocular retinoids after isotretinoin and an intense bleach showed decreased leve
30 sotretinoin) or immunotherapy (six cycles of isotretinoin and five concomitant cycles of ch14.18 in c
31                                   Apart from isotretinoin and hormonal therapy, no agents are availab
32  published and unpublished studies assessing isotretinoin and IBD used a random-effects model to esti
33 conflicting regarding an association between isotretinoin and inflammatory bowel disease.
34             Terms related to acne treatment, isotretinoin, and diagnostic procedures were searched wi
35 sacea unresponsive to oral doxycycline, oral isotretinoin, and topical tacrolimus.
36 therapies, such as corticosteroids, dapsone, isotretinoin, and/or antibiotics.
37 eptives in acne, and the use and efficacy of isotretinoin are also addressed.
38  suggests that significantly higher doses of isotretinoin are effective for treating acne and decreas
39 ockers, antipsychotics, antidepressants, and isotretinoin are linked to dry eye disease.
40 oral conceptive agents or spironolactone, or isotretinoin are most effective.
41 al contraception [COC] or spironolactone, or isotretinoin) are recommended for more severe disease.
42  ivermectin, as well as oral doxycycline and isotretinoin, are associated with improvements in rosace
43 opathic PPD, and it is important to consider isotretinoin as a potential inciting agent.
44                               Perceptions of isotretinoin-associated risks and understanding of ways
45 f isotretinoin) or retrial (retreatment with isotretinoin) at 12-month follow-up and adverse effects
46                                              Isotretinoin blocked the formation of A2E biochemically
47                                   The median isotretinoin course duration was 6 months (IQR, 4.0-8.0)
48 Female sex (HR, 0.68; 95% CI, 0.62-0.76) and isotretinoin cumulative dosage (HR, 0.99; 95% CI, 0.98-0
49 ed with increased rates of acne relapse, and isotretinoin cumulative dosage (mg/kg) was associated wi
50                                              Isotretinoin does not impair PSA decline or add signific
51 and vincristine with or without 12 cycles of isotretinoin during and following maintenance.
52                 This study demonstrates that isotretinoin exerts immunomodulatory effects in patients
53 wel disease developed less frequently in the isotretinoin-exposed group vs the nonexposed group (0.9%
54 tinoin, new strategies for reducing rates of isotretinoin-exposed pregnancies are needed.
55                                     However, isotretinoin-exposed pregnancies continue to occur.
56                            Risk of IBD among isotretinoin-exposed vs non exposed patients.RESULTS Bot
57 p included the patients with confirmed prior isotretinoin exposure (n = 576), and the nonexposed grou
58             The negative association between isotretinoin exposure and IBD remained after adjusting f
59 ily seeking acne treatment were reviewed for isotretinoin exposure.
60 ainly in patients with acne with and without isotretinoin exposure.DESIGN, SETTING, AND PARTICIPANTS
61  who were 12 years or older and had received isotretinoin for 4 months or longer, with at least 1 yea
62 er-affirming hormonal therapy and prescribed isotretinoin for the management of acne between August 1
63 ry testing for use of standard doses of oral isotretinoin for the standard patient with acne.
64  lower extremities 2 months after initiating isotretinoin for the treatment of refractory nodulocysti
65 ogen treatment to add (arm 1) or not (arm 2) isotretinoin from weeks 1 to 12.
66 1 discontinued while patients in arm 2 added isotretinoin from weeks 14 to 25.
67 sequent treatment with 13-cis-retinoic acid (isotretinoin) further improves event-free survival.
68                                         Oral isotretinoin has been associated with several adverse ef
69 tive trials include the possible activity of isotretinoin in never and former smokers and that of alp
70 by AS-OCT before and after treatment by oral isotretinoin in patients of acne vulgaris (AV).
71  both showed slow recovery from bleach after isotretinoin in rats and in mice.
72 nol, retinyl palmitate, N-acetylcysteine, or isotretinoin in smokers.
73 n MEK inhibitors (trametinib) and retinoids (isotretinoin) in primary nf1a-/- zebrafish neuroblastoma
74                   Our analysis revealed that isotretinoin induced significant early and sustained sup
75 y be a useful addition to efforts to prevent isotretinoin-induced birth defects.
76  to our knowledge the first reported case of isotretinoin-induced PPD.
77                         We hypothesized that isotretinoin induces remission of acne by normalizing th
78                                        While isotretinoin is a highly effective acne treatment, littl
79                                              Isotretinoin is a pro-drug for all-trans retinoic acid,
80                                              Isotretinoin is a widely prescribed medication for nodul
81                                              Isotretinoin is approved by the US Food and Drug Adminis
82           This meta-analysis showed that (1) isotretinoin is associated with a statistically signific
83                                              Isotretinoin is frequently prescribed for the treatment
84                                              Isotretinoin is hypothesized to contribute to the develo
85         Participants clearly understood that isotretinoin is teratogenic but had less understanding o
86                                         Oral isotretinoin is the most effective therapy and is used e
87                                              Isotretinoin is the most effective treatment for acne.
88                                              Isotretinoin is the only medical acne treatment capable
89                                   IMPORTANCE Isotretinoin is the standard treatment for refractory se
90                        13 cis Retinoic acid (isotretinoin) is a retinoid with preclinical evidence of
91 er participants could reach consensus on key isotretinoin laboratory monitoring parameters.
92            Finally, the results suggest that isotretinoin may be an effective treatment for other for
93 nflammatory and immune-modulating effects of isotretinoin may be worth exploring.
94    Further, they suggest that treatment with isotretinoin may inhibit lipofuscin accumulation and thu
95                                     Although isotretinoin may rarely be associated with laboratory ab
96  the iPLEDGE program increases anxiety about isotretinoin more than it helps women feel protected fro
97 ntly reduced rates of pregnancies exposed to isotretinoin, new strategies for reducing rates of isotr
98        Accordingly, we tested the effects of isotretinoin on lipofuscin accumulation in abcr(-/-) kno
99  were defined as patients who never received isotretinoin or received it after the diagnosis of IBD (
100 , to receive standard therapy (six cycles of isotretinoin) or immunotherapy (six cycles of isotretino
101 al or oral acne medication after a course of isotretinoin) or retrial (retreatment with isotretinoin)
102      Exclusion criteria were use of modified isotretinoin products, isotretinoin therapy for conditio
103                                              Isotretinoin randomization was closed early owing to fut
104                                              Isotretinoin reduced Ca2+ entry in HaCaT cells and decre
105 ncluded 1078 patients from 1995 to 2011,with isotretinoin referenced in their medical records, and wh
106                                     Frequent isotretinoin-related toxicity included grade 1 cheilitis
107 iated with decreased risk of acne relapse or isotretinoin retrial among those with conventional and h
108 t negatively associated with acne relapse or isotretinoin retrial in patients with cumulative dosage
109 (22.5%) had acne relapse and 1639 (8.2%) had isotretinoin retrial.
110 .99) were associated with decreased rates of isotretinoin retrial.
111 atment characteristics with acne relapse and isotretinoin retrial.
112  potentially reduce risk of acne relapse and isotretinoin retrial.
113  These findings enhance our understanding of isotretinoin's mechanism and highlight mTORC1 as a poten
114 mTOR inhibitors as top candidates that mimic isotretinoin's transcriptomic signature.
115                                              Isotretinoin significantly decreased lipogenesis, while
116                   Treatment of patients with isotretinoin significantly decreased monocyte TLR-2 expr
117  showed, however, that even a single dose of isotretinoin slowed the recovery of rod signaling after
118                     The notion that systemic isotretinoin taken within 6 to 12 months of cutaneous su
119                                              Isotretinoin, the gold-standard treatment for severe acn
120 kin of 18 patients with severe acne prior to isotretinoin therapy (baseline) and after 1, 8, and 20 w
121 14.18, GM-CSF, and interleukin-2 to standard isotretinoin therapy after intensive multimodal therapy
122 cuss the pathophysiologic characteristics of isotretinoin therapy and the likely causative role that
123  were use of modified isotretinoin products, isotretinoin therapy for conditions other than acne vulg
124                                              Isotretinoin therapy for the management of acne.
125                                     Systemic isotretinoin therapy has achieved nearly complete resolu
126 based estimates of laboratory changes during isotretinoin therapy in large patient samples are limite
127      Although rare, lip abscesses related to isotretinoin therapy present with substantial morbidity
128 ing more time-specific monitoring throughout isotretinoin therapy were asked in subsequent rounds.
129 ediately following the cessation of systemic isotretinoin therapy.
130 ently receiving or having recently completed isotretinoin therapy.
131 rgical procedures in the setting of systemic isotretinoin therapy.
132  A derivative, the dietary administration of isotretinoin to flavivirus-infected animals interrupted
133 antigen (PSA) decline and toxicity of adding isotretinoin to hormonal therapy and, secondarily, the p
134 esponsible for night vision, we administered isotretinoin to rats to learn whether night blindness re
135 g alpha-adrenergic receptors synergizes with isotretinoin to suppress growth and to promote different
136 tudy participants were 16 women who had used isotretinoin to treat severe skin disease and who were r
137 tabolic panel parameters at any point during isotretinoin treatment (all >70%); do not check gamma-gl
138 ecause the lesions began after initiation of isotretinoin treatment and resolved shortly after its te
139                                              Isotretinoin treatment causes statistically significant
140  for both the clinician and the patient when isotretinoin treatment is indicated.OBJECTIVE To assess
141                                     However, isotretinoin treatment may be necessary in some patients
142 der-affirming hormonal therapy and underwent isotretinoin treatment, isotretinoin was often effective
143                At 1 year after completion of isotretinoin treatment, we found that patients receiving
144 e not recommended in the setting of systemic isotretinoin treatment.
145 patients for signs of mental distress during isotretinoin treatment.
146 cystic acne.A true association between prior isotretinoin use and development of inflammatory bowel d
147 1, 2013) to identify all relevant studies of isotretinoin use in acne vulgaris.
148 not show an increased risk of IBD with prior isotretinoin use.
149 findings suggest that at a population level, isotretinoin users do not have increased risk of suicide
150  associated with psychiatric disorders among isotretinoin users remain unclear.
151                                              Isotretinoin users were less likely than nonusers to att
152 ) of suicide and psychiatric disorders among isotretinoin users.
153  for suicide and psychiatric disorders among isotretinoin users.
154                                              Isotretinoin was also found to protect rat photoreceptor
155                                              Isotretinoin was associated with improvement in 48 patie
156 tic surgery, scars, wound healing, acne, and isotretinoin was convened.
157                                    High-dose isotretinoin was given daily for 2 months and produced s
158                                              Isotretinoin was not associated with the risk of all psy
159 herapy and underwent isotretinoin treatment, isotretinoin was often effective and well tolerated.
160                                   We believe isotretinoin was the most likely causative agent in this
161    Topical acne treatments, antibiotics, and isotretinoin were used successfully in these patients, r
162  induced by the therapeutic vitamin A analog isotretinoin, which protected against skin infection in
163 oncerns regarding the use of antibiotics and isotretinoin will be addressed.
164                            Patients received isotretinoin, with dosing based on the providers' judgme

 
Page Top